Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCI699 dose-ranging study in resistant hypertension
2008-007338-23Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of osilodrostat in resistant hypertension (RH) and hypertension (HTN) (5 arms), sponsored by Novartis. Primary endpoint: Primary efficacy endpoint. Started Jan 2009; status: completed.
02
Drugs
osilodrostat
03
Conditions
resistant hypertension (RH)hypertension (HTN)
Beyond the preview
Go deeper on 2008-007338-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007338-23.